Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AMIX 
Autonomix Medical, Inc. Common Stock (AMIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: AMIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.6
1 Year Target Price $6.6
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.88M USD | Price to earnings Ratio - | 1Y Target Price 6.6 |
Price to earnings Ratio - | 1Y Target Price 6.6 | ||
Volume (30-day avg) 2 | Beta - | 52 Weeks Range 0.96 - 17.15 | Updated Date 10/17/2025 |
52 Weeks Range 0.96 - 17.15 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.33 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -95.2% | Return on Equity (TTM) -195.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3443849 | Price to Sales(TTM) - |
Enterprise Value -3443849 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 6194147 | Shares Floating 4835772 |
Shares Outstanding 6194147 | Shares Floating 4835772 | ||
Percent Insiders 7.73 | Percent Institutions 4.76 |
Upturn AI SWOT
Autonomix Medical, Inc. Common Stock
Company Overview
History and Background
Autonomix Medical, Inc. is a medical device company focused on developing and commercializing innovative solutions for improving the diagnosis and treatment of chronic diseases. They aim to address unmet needs in autonomic nervous system disorders.
Core Business Areas
- Autonomic Nervous System Mapping: Developing technologies for precise mapping of the autonomic nervous system to guide targeted therapies.
- Minimally Invasive Devices: Creating minimally invasive devices for therapeutic interventions on the autonomic nervous system.
Leadership and Structure
Details regarding the leadership team and organizational structure are limited as a public entity and therefore can not be provided.
Top Products and Market Share
Key Offerings
- Company Focus: Autonomix Medical is focused on developing their first product (currently unnamed) to address unmet needs in the autonomic nervous system. Since the company is in early stage it has no revenue data to report and no current market share. Competitors at this stage are other early stage companies who are involved in developing similar medical devices.
Market Dynamics
Industry Overview
The medical device industry is highly competitive and rapidly evolving, with continuous innovation in diagnostic and therapeutic technologies. Autonomic nervous system interventions are an emerging area with significant growth potential.
Positioning
Autonomix Medical aims to establish a leadership position in the autonomic nervous system space by offering innovative mapping and therapeutic solutions. Given their early development stage, their competitive advantage depends on successful product development and commercialization.
Total Addressable Market (TAM)
The TAM for autonomic nervous system interventions is difficult to precisely quantify, but it represents a significant market opportunity. Autonomix Medical is positioned to capture a portion of this TAM by offering novel diagnostic and therapeutic solutions.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Focus on unmet needs in autonomic nervous system disorders
- Experienced management team (specifics not publicly available)
Weaknesses
- Early-stage company with limited product pipeline
- High reliance on successful product development and regulatory approval
- Limited financial resources
Opportunities
- Growing demand for minimally invasive therapies
- Partnerships with leading medical institutions and physicians
- Expansion into new therapeutic areas
Threats
- Competition from established medical device companies
- Regulatory hurdles and clinical trial risks
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- Companies that are competitors do not have a stock symbol.
Competitive Landscape
The company's competitive advantage lies in its innovative approach to autonomic nervous system mapping and therapy. However, it faces competition from larger, more established medical device companies.
Growth Trajectory and Initiatives
Historical Growth: Due to the companies early status there is no growth trajectory.
Future Projections: Future growth is contingent upon successful product development, regulatory approval, and commercialization. Analyst estimates are unavailable given the company's early stage.
Recent Initiatives: Recent initiatives revolve around advancing its lead product candidate through preclinical and clinical development.
Summary
Autonomix Medical is an early-stage medical device company focused on innovative technologies for autonomic nervous system disorders. Its success hinges on the successful development and commercialization of its lead product candidate. It faces challenges related to competition, regulatory hurdles, and financing. The company's innovative approach offers potential for growth in this emerging market if they can successfully navigate the challenges of being an early stage public company. With limited financial data the company is a speculation investment at this time.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Financial data is limited due to the company's early stage. Market share data is based on limited information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Autonomix Medical, Inc. Common Stock
Exchange NASDAQ | Headquaters The Woodlands, TX, United States | ||
IPO Launch date 2024-01-29 | CEO & President Mr. Bradley Hauser | ||
Sector Healthcare | Industry Medical Devices | Full time employees 8 | Website https://autonomix.com |
Full time employees 8 | Website https://autonomix.com | ||
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company's technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.